Latest:
Dr. Otterson on the Utility of Immunotherapy in NSCLC
Gregory A. Otterson, MD, discusses data examining immunotherapy alone versus in combination in non–small cell lung cancer.
- Advertise
- About OncLive
- Editorial Board
- MJH Life Sciences brands
- Contact Us
- Privacy
- Terms & Conditions
- Do Not Sell My Information
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
© 2025 MJH Life Sciences™ and OncLive - Clinical Oncology News, Cancer Expert Insights. All rights reserved.
Authors
Gregory E. Idos, MD
Latest:
Dr. Idos on Remaining Questions With Multiplex Panel Testing
Gregory E. Idos, MD, assistant professor of Clinical Medicine, Department of Surgery, Division of Colorectal Surgery, Keck School of Medicine of University of Southern California, sheds light on the remaining questions with multiplex panel testing as well as the cost effectiveness of it.
Gregory L. Beatty, MD, PhD
Latest:
Dr. Beatty on the Potential for Immunotherapy in GI Malignancies
Gregory L. Beatty, MD, PhD, assistant professor of medicine, director of Tanslation Research, Pancreatic Cancer Research Center, University of Pennsylvania Perelman School of Medicine, discusses the potential for immunotherapy in gastrointestinal malignancies.
Gregory Springett MD PhD
Latest:
Phase II Clinical Trial of Intratumoral Dendritic Cells Injections and Neoadjuvant Radiotherapy in Resectable Soft Tissue Sarcomas
Neoadjuvant radiation with dendritic cell injections has the potential to be safe, effective, and immunogenic in high-grade soft tissue sarcoma and needs to be confirmed in randomized larger clinical trials.
Gregory Vidal, MD, PhD
Latest:
Patient-Centered Decisions and Evolving Treatment Landscape for HER2+ Metastatic Breast Cancer
Panelists discuss how treatment decisions in later-line settings should incorporate clinical trials, patient preferences regarding quality of life, medication scheduling, financial considerations, and previous adverse effect experiences, while also addressing special considerations for brain metastases.
Gregory Zagaja, MD
Latest:
Dr. Zagaja on Major Benefit With Prostatectomy
Gregory Zagaja, MD, professor of Surgery, director of the Prostate Cancer Center at the University of Chicago Medicine, discusses the benefits of radical prostatectomy for patients with prostate cancer. Zagaja shared this insight during an interview at the 2016 OncLive State of the Science Summit on GU and Prostate Cancer.
Grzegorz S. Nowakowski, MD
Grzegorz S. Nowakowsi, MD, a consultant in the Division of Hematology in the Department of Internal Medicine and the Enterprise Deputy Director of Clinical Research at the Mayo Clinic Comprehensive Cancer Center
Latest:
Dr Nowakowski on the FDA Approval of Brentuximab Vedotin for R/R LBCL
Grzegorz S. Nowakowsi, MD, discusses the unique mechanism of action of brentuximab vedotin plus lenalidomide and rituximab in relapsed/refractory LBCL.
Grzegorz S. Nowakowski, MD, Mayo Clinic
Latest:
Five-year Efficacy and Safety of Tafasitamab in Patients With Relapsed or Refractory DLBCL: Final Results From the Phase II L-MIND Study
Expert hematologist-oncologist Grzegorz Nowakowski, MD, reviews data from the 5-year analysis of the L-MIND study combining tafasitamab with lenalidomide in relapsed/refractory diffuse large B-cell lymphoma.
Guillermo Garcia-Manero, MD
Guillermo Garcia-Manero, MD, is director of the Fellowship Program, the Dr. Kenneth B. McCredie Chair in Clinical Leukemia Research, deputy chair of Translational Research, a professor, and chief of the Section of Myelodysplastic Syndromes in the Department of Leukemia, as well as leader of the MDS/AML Moon Shot Program at The University of Texas MD Anderson Cancer Center in Houston.
Latest:
Key Areas of Ongoing Research in MDS
Guillermo Garcia-Manero, MD, discusses ongoing research to watch in MDS.
Guiseppe Visani, MD
Latest:
Dr. Visani on Tosedostat and Cytarbine in Elderly Patients With AML
Guiseppe Visani, MD, director, Hematology and Stem Cell Transplant Center at AORMN, Pesaro, Italy, discusses a phase II study examining the efficacy of tosedostat plus low-dose cytarabine in elderly patients with acute myeloid leukemia.
Gunter von Minckwitz, MD
Latest:
Dr. von Minckwitz on Lessons Learned From Neoadjuvant Trials in Breast Cancer
Gunter von Minckwitz, MD, director of the German Breast Group Research Institute, discusses lessons learned from clinical trials examining neoadjuvant therapies in patients with breast cancer.
Gunter von Minckwitz, MD, PhD
Latest:
Dr. von Minckwitz on the Safety Profile of the APHINITY Trial for HER2+ Breast Cancer
Gunter von Minckwitz, MD, PhD, president of the German Breast Group in Neu-Isenburg, Germany, discusses the safety profile of the phase III APHINITY trial for patients with HER2-positive breast cancer.